Researchers are testing the effectiveness of Metformin to help improve daily living for individuals with Fragile X Syndrome (FXS)
Why do this study?
We are attempting to further assess Metformin’s safety, as well as the benefits of the drug, which has been shown to improve the symptoms and difficulties which individuals with FXS experience, including: delayed language/cognition, excessive eating, obesity, hypogonadism, and delayed puberty.
What the participants will do?
Commit to a 4-month study which includes 3 clinic visits, and 5 phone calls while taking Metformin orally. Complete various tasks, questionnaires, and examinations by a physician/research team, as well as have blood drawn, as well as urine and stool samples taken.
Who Can Participate?
Individuals aged 6-25 who have been diagnosed with FXS (and who fit the inclusion/exclusion criteria).
Where is the study being conducted?
There are two sites: the University of Alberta and Ste Justine in Montreal. Travel expenses will be reimbursed.
This project is titled: “A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals with Fragile X Syndrome (FXS)”. The principal investigator of this study is Dr. Francois Bolduc, MD, PhD, FRCPC, in the Department of Pediatrics at the University of Alberta.
View More Opportunites
If you’d like to learn more or apply for this opportunity, please fill out the form to send your contact information to the study coordinators.